# Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

> **NCT06584032** · PHASE3 · RECRUITING · sponsor: **Hutchmed** · enrollment: 412 (estimated)

## Conditions studied

- Advanced Endometrial Cancer

## Interventions

- **DRUG:** fruquintinib
- **BIOLOGICAL:** sintilimab
- **DRUG:** paclitaxel
- **DRUG:** doxorubicin

## Key facts

- **NCT ID:** NCT06584032
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2029-01-08
- **Final completion:** 2029-06-09
- **Target enrollment:** 412 (ESTIMATED)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06584032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06584032, "Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06584032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*